0000950170-24-075603.txt : 20240620 0000950170-24-075603.hdr.sgml : 20240620 20240620162100 ACCESSION NUMBER: 0000950170-24-075603 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20240620 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20240620 DATE AS OF CHANGE: 20240620 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Clearside Biomedical, Inc. CENTRAL INDEX KEY: 0001539029 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 452437375 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37783 FILM NUMBER: 241056529 BUSINESS ADDRESS: STREET 1: 900 NORTH POINT PARKWAY STREET 2: SUITE 200 CITY: ALPHARETTA STATE: GA ZIP: 30005 BUSINESS PHONE: 678-270-3631 MAIL ADDRESS: STREET 1: 900 NORTH POINT PARKWAY STREET 2: SUITE 200 CITY: ALPHARETTA STATE: GA ZIP: 30005 8-K 1 clsd-20240620.htm 8-K 8-K
0001539029false00015390292024-06-202024-06-20

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 20, 2024

 

 

Clearside Biomedical, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-37783

45-2437375

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

900 North Point Parkway

Suite 200

 

Alpharetta, Georgia

 

30005

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 678 270-3631

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.001 per share

 

CLSD

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 20, 2024, Clearside Biomedical, Inc. (the “Company”) held its 2024 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders considered three proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 26, 2024 (the “Proxy Statement”). Of the 74,731,139 shares outstanding as of the record date, 50,056,288 shares, or 67%, were present or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting.

Proposal No. 1: Election of three nominees to serve as directors until the 2027 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows:

Name

Votes For

Votes Withheld

 

Broker Non-Votes

Richard Croarkin

30,202,533

4,445,629

15,408,126

William D. Humphries

30,187,760

4,449,070

15,419,458

Nancy J. Hutson

29,492,996

5,146,798

15,416,494

All nominees were elected.

Proposal No. 2: Approval, on an advisory basis, of the compensation paid to the Company’s named executive officers, as disclosed in the Proxy Statement. The votes were cast as follows:

Votes For

Votes Against

Abstained

Broker Non-Votes

Advisory approval of the compensation paid to the named executive officers

22,811,768

5,237,370

 

6,599,024

 

15,408,126

 

Proposal No. 3: Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024. The votes were cast as follows:

Votes For

 

Votes Against

 

Abstained

Ratification of appointment of Ernst & Young LLP

45,119,612

 

4,880,367

 

56,309

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 20, 2024

CLEARSIDE BIOMEDICAL, INC.

 

 

By:

/s/ Charles A. Deignan

Name:

Charles A. Deignan

Title:

Chief Financial Officer

 

 EX-101.SCH 2 clsd-20240620.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 4 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Document And Entity Information
Jun. 20, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 20, 2024
Entity Registrant Name Clearside Biomedical, Inc.
Entity Central Index Key 0001539029
Entity Emerging Growth Company false
Entity File Number 001-37783
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 45-2437375
Entity Address, Address Line One 900 North Point Parkway
Entity Address, Address Line Two Suite 200
Entity Address, City or Town Alpharetta
Entity Address, State or Province GA
Entity Address, Postal Zip Code 30005
City Area Code 678
Local Phone Number 270-3631
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol CLSD
Security Exchange Name NASDAQ
EXCEL 5 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 6 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 7 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 9 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://clearsidebio.com/20240620/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports clsd-20240620.htm clsd-20240620.xsd http://xbrl.sec.gov/dei/2024 false false JSON 11 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "clsd-20240620.htm": { "nsprefix": "clsd", "nsuri": "http://clearsidebio.com/20240620", "dts": { "inline": { "local": [ "clsd-20240620.htm" ] }, "schema": { "local": [ "clsd-20240620.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 23 }, "report": { "R1": { "role": "http://clearsidebio.com/20240620/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_f8a92d5d-605f-4422-9404-f0e9063b850e", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "clsd-20240620.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f8a92d5d-605f-4422-9404-f0e9063b850e", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "clsd-20240620.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://clearsidebio.com/20240620/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://clearsidebio.com/20240620/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://clearsidebio.com/20240620/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://clearsidebio.com/20240620/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://clearsidebio.com/20240620/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://clearsidebio.com/20240620/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://clearsidebio.com/20240620/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://clearsidebio.com/20240620/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://clearsidebio.com/20240620/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://clearsidebio.com/20240620/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://clearsidebio.com/20240620/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://clearsidebio.com/20240620/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://clearsidebio.com/20240620/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://clearsidebio.com/20240620/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://clearsidebio.com/20240620/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://clearsidebio.com/20240620/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://clearsidebio.com/20240620/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://clearsidebio.com/20240620/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://clearsidebio.com/20240620/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://clearsidebio.com/20240620/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://clearsidebio.com/20240620/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://clearsidebio.com/20240620/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://clearsidebio.com/20240620/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 12 0000950170-24-075603-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-075603-xbrl.zip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end XML 14 clsd-20240620_htm.xml IDEA: XBRL DOCUMENT 0001539029 2024-06-20 2024-06-20 0001539029 false 8-K 2024-06-20 Clearside Biomedical, Inc. DE 001-37783 45-2437375 900 North Point Parkway Suite 200 Alpharetta GA 30005 678 270-3631 false false false false Common Stock, par value $0.001 per share CLSD NASDAQ false